-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 15, Xi'an Jansen Pharmaceuticals released the latest data from VOYAGE 2, a long-term clinical trial of Tremfya (guselkumab) for patients with plaque yandr.
results showed that Tremfya showed good consistency and high skin removal rates at two time baselines at 100 weeks and 204 weeks (four years).
in open-label extended trial VOYAGE 2, 80 percent of patients treated with 100mg Tremfya every 8 weeks achieved an improvement in psoriasis area and severity index by more than 90% in the fourth year; 82% of patients achieved a researcher's global assessment (IGA) score of 0 (for removal) or 1 (for mild disease); 51% of patients reached PASI 100 or completely removed psoriasis.
the data has been received by the American Academy of Dermatose at its annual general meeting and shared online as a poster (P15300).
the clinical endpoint of VOYAGE 2 also includes patient-reported outcome assessments, including the Skin Disease Quality of Life Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD).
in the fourth year, 69% of patients had a DLQI score of 0 or 1 (obvious skin disease had no effect on health quality of life), 40% had a PSSD symptom score of 0 (asymptomatic state), and 27% had PSSD signs hidden to 0 (no signs).
in voyage 2 trials, the safety of Tremfya and Adamu monoause is consistent with the safety information provided in the current prescription information. Professor Kristian Reichi, lead researcher of the voyage 2 study,
, said: "Long-term remission of psoriasis is important for improving the quality of life of patients, and the results of the VOYAGE 2 study show that Tremfya can have therapeutic effects for up to 4 years and provide long-term treatment options for patients with chronic psoriasis. in addition, comparison data on clinical outcomes reported by patients with Thetagain's head-to-head randomized phase 3 clinical trial VOYAGE 1 have been shared via the online poster (P15287).
results showed that at the 48th week, 42% of the patients in the Tremfya treatment group achieved asymptomatic, i.e. PSSD symptom score was 0, the proportion of Adamu monotodrine group was 23%, and 35% of patients in the Tremfya treatment group achieved atotal, i.e. PSSD sign score was 0, and the Adamu monoantitic group was 19%.
and during the 48-week treatment, patients in the Tremfya treatment group had no symptoms such as itching, pain, cracking or scaly skin for longer than the Adamu monotomatism group.
Reference Source: New Phase 3 Data for TREMFYA® , a First-in-Class IL-23 p19 Subunit Put, Show Consistent, High Levels of The Rand Son Son S.